
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **IGKV1-12, IGLL5, IGLV3-1, IGHG1, IGHG2, IGHG3, IGKC, IGHM, IGHG4**: These are immunoglobulin (Ig) genes, which are critical components of antibodies. They are involved in the immune response, specifically in antigen recognition and binding.<br>- **JCHAIN**: This gene encodes the joining chain of multimeric IgA and IgM, which is important for the polymerization of these immunoglobulins.<br>- **CD79A**: Part of the B-cell receptor complex, essential for B-cell development and signaling.<br>- **POU2AF1**: A transcriptional coactivator involved in B-cell-specific transcription.<br>- **FCRL5, TNFRSF17, SLAMF7**: These are receptors and signaling molecules associated with B-cell activation and differentiation.<br>- **CD38**: A multifunctional enzyme and receptor involved in cell adhesion, signal transduction, and calcium signaling, often expressed in plasma cells.<br>- **MZB1**: A chaperone protein involved in immunoglobulin folding and assembly, highly expressed in plasma cells.<br>- **ST6GAL1**: An enzyme involved in the sialylation of glycoproteins, which can be important in immune cell interactions.<br><br>### Step 2: List the Key Cell Type Markers<br>- **IGKV1-12, IGLL5, IGLV3-1, IGHG1, IGHG2, IGHG3, IGKC, IGHM, IGHG4**: These markers are indicative of B cells, particularly mature B cells and plasma cells.<br>- **CD79A**: A marker for B cells, part of the B-cell receptor complex.<br>- **CD38, MZB1, SLAMF7**: These are markers commonly associated with plasma cells, a differentiated form of B cells that produce antibodies.<br>- **POU2AF1**: Associated with B-cell lineage, particularly in the context of transcriptional regulation.<br><br>### Step 3: Cross-reference Known Databases<br>Using scRNA-seq databases such as the Human Cell Atlas and literature on breast cancer tissue, the expression of these markers is consistent with B cells, particularly plasma cells. Plasma cells are known to infiltrate breast cancer tissues and are involved in the immune response against tumors.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of immunoglobulin genes, CD79A, CD38, and MZB1, the most probable general cell type is **B cells**, with a strong indication towards **plasma cells** due to the high expression of immunoglobulin genes and plasma cell-specific markers.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Plasma Cells**: The high expression of immunoglobulin genes, CD38, MZB1, and SLAMF7 strongly suggests plasma cells, which are antibody-secreting cells derived from B cells.<br>2. **Memory B Cells**: While less likely due to the high expression of plasma cell markers, memory B cells can express some immunoglobulin genes and CD79A.<br>3. **Activated B Cells**: These cells can express a range of immunoglobulin genes and are involved in active immune responses, but the specific markers here lean more towards plasma cells.<br><br>The most likely subtype based on the markers is **Plasma Cells**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset indicates that the cell cluster is most likely composed of plasma cells. This conclusion is supported by the high expression of immunoglobulin genes, CD38, MZB1, and other plasma cell-specific markers. Plasma cells are a differentiated form of B cells that play a crucial role in the immune response by producing antibodies, and their presence in breast cancer tissue can be indicative of an immune response to the tumor.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**: <br>   - The key functional markers and cell type markers listed in the annotation are present in the provided marker list. <br>   - The markers such as IGKV1-12, IGLL5, IGLV3-1, IGHG1, IGHG2, IGHG3, IGKC, IGHM, IGHG4, CD79A, CD38, MZB1, SLAMF7, and POU2AF1 are all indicative of B cells, particularly plasma cells, which aligns with the annotation.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The annotation acknowledges the possibility of memory B cells and activated B cells but concludes that plasma cells are the most likely subtype due to the strong expression of plasma cell-specific markers. <br>   - There is no strong evidence of multiple distinct cell types that would necessitate flagging for mixed cell type consideration.<br><br>The annotation correctly identifies the cell cluster as primarily composed of plasma cells, supported by the high expression of immunoglobulin genes and other plasma cell-specific markers. The analysis is thorough and aligns with known databases and literature on breast cancer tissue, confirming the presence of plasma cells in the immune response against tumors.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">B cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Plasma Cells</li><li>Memory B Cells</li><li>Activated B Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided for the single-cell dataset derived from human breast cancer tissue are generally well-executed, with a strong focus on identifying the cell type based on the ranked marker list. Here are the key points of evaluation:<br><br>1. **Correctness of Annotations**: The annotation correctly identifies the cell cluster as primarily composed of plasma cells, which is supported by the high expression of immunoglobulin genes (e.g., IGKV1-12, IGLL5, IGHG1, IGHG2, IGHG3, IGKC, IGHM, IGHG4) and other plasma cell-specific markers such as CD38 and MZB1. This is consistent with the known biology of plasma cells, which are antibody-secreting cells derived from B cells.<br><br>2. **Balanced Consideration of Multiple Markers**: The analysis effectively balances the use of different markers, considering both immunoglobulin genes and other markers like CD79A, POU2AF1, and SLAMF7. This comprehensive approach ensures that the annotation is not overly reliant on a single marker but rather considers the collective expression profile.<br><br>3. **General Picture of Cell Populations**: The annotation provides a comprehensive view of the cell types present, acknowledging the possibility of memory B cells and activated B cells, although it concludes that plasma cells are the most likely subtype. This reflects an understanding of the potential diversity within the B cell lineage in the context of breast cancer tissue.<br><br>4. **Consideration of Marker Rank**: The annotation does not explicitly discuss the rank of the markers, which could be an area for improvement. While the presence of immunoglobulin genes is emphasized, a more detailed discussion on the significance of marker rank could enhance the analysis.<br><br>5. **Scientific Accuracy**: The annotation aligns with known databases and literature on breast cancer tissue, confirming the presence of plasma cells in the immune response against tumors. This scientific grounding adds credibility to the results.<br><br>Overall, the annotation is scientifically accurate, well-balanced in its use of markers, and provides a comprehensive view of the cell populations. The main area for improvement is a more explicit consideration of the rank of the markers, which could further refine the analysis.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    